title: Towards an immunotherapy for p185HER2 overexpressing tumors.
authors.affiliation: Department of Protein Engineering, Genentech Inc., South San Francisco, CA 94080.
authors.forename: P
authors.initials: P
authors.lastname: Carter
authors.forename: M L
authors.initials: ML
authors.lastname: Rodrigues
authors.forename: G D
authors.initials: GD
authors.lastname: Lewis
authors.forename: I
authors.initials: I
authors.lastname: Figari
authors.forename: M R
authors.initials: MR
authors.lastname: Shalaby
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000276:immunology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D017252:CD3 Complex / Q000276:immunology; D066246:ErbB Receptors / Q000276:immunology; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007167:Immunotherapy; D000922:Immunotoxins / Q000276:immunology / Q000627:therapeutic use; D051379:Mice; D008819:Mice, Nude; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D015202:Protein Engineering; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis* / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use*; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014407:Tumor Cells, Cultured
chemical_list: D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D066246:ErbB Receptors; D000922:Immunotoxins; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins